{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:47Z","timestamp":1792791947860,"version":"4.5.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,13]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>More than 80% of patients with PMF harbor DNA variants\/mutations other than JAK2\/CALR\/MPL. Some of these variants\/mutations adversely affect overall or leukemia-free survival independent of conventional risk stratification.<\/jats:p>","DOI":"10.1182\/bloodadvances.2016000208","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T16:34:09Z","timestamp":1480523649000},"page":"105-111","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":211,"title":["Targeted deep sequencing in primary myelofibrosis"],"prefix":"10.1182","volume":"1","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M.","family":"Finke","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoseph","family":"Elala","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Laboratory Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"issue":"1","key":"2019111607053484900_B1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative Neoplasms: A Contemporary Review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"2019111607053484900_B2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2019111607053484900_B3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111607053484900_B4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111607053484900_B5","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3324\/haematol.13266","article-title":"Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations","volume":"93","author":"Vannucchi","year":"2008","journal-title":"Haematologica"},{"key":"2019111607053484900_B6","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111607053484900_B7","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"2019111607053484900_B8","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"20","key":"2019111607053484900_B9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2019111607053484900_B10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111607053484900_B11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ajh.23678","article-title":"CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum","volume":"89","author":"Guglielmelli","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111607053484900_B12","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"2019111607053484900_B13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111607053484900_B14","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"15","key":"2019111607053484900_B15","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111607053484900_B16","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111607053484900_B17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111607053484900_B18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111607053484900_B19","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111607053484900_B20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/leu.2014.277","article-title":"SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation","volume":"29","author":"Bartels","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"2019111607053484900_B21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2013.286","article-title":"U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111607053484900_B22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccell.2015.04.008","article-title":"Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo","volume":"27","author":"Shirai","year":"2015","journal-title":"Cancer Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/2\/105\/877645\/advances000208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/2\/105\/877645\/advances000208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T07:05:42Z","timestamp":1573887942000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/2\/105\/15525\/Targeted-deep-sequencing-in-primary-myelofibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,12,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2016000208","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]}}}